Protalix BioTherapeutics (PLX) Hisse Özeti
Bir biyofarmasötik şirketi olan Protalix BioTherapeutics, Inc. ProCellEx bitki hücresi tabanlı protein ekspresyon sistemine dayalı rekombinant terapötik proteinlerin geliştirilmesi, üretimi ve ticarileştirilmesi ile ilgilenmektedir. Daha fazla detay
| Kar Tanesi Skoru | |
|---|---|
| Değerleme | 3/6 |
| Gelecekteki Büyüme | 0/6 |
| Geçmiş Performans | 6/6 |
| Finansal Sağlık | 6/6 |
| Temettüler | 0/6 |
PLX Community Fair Values
Create NarrativeSee what 56 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$4.23
FV
43.7% değerinin altında içsel indirim14.00%
Revenue growth p.a.
348
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
13users have followed this narrative
Protalix BioTherapeutics, Inc. Rakipler
Fiyat Geçmişi ve Performans
| Tarihsel hisse senedi fiyatları | |
|---|---|
| Güncel Hisse Fiyatı | US$2.38 |
| 52 Haftanın En Yüksek Seviyesi | US$3.19 |
| 52 Haftanın En Düşük Seviyesi | US$1.41 |
| Beta | -0.0024 |
| 1 Aylık Değişim | 7.21% |
| 3 Aylık Değişim | 7.21% |
| 1 Yıllık Değişim | 56.58% |
| 3 Yıllık Değişim | 47.83% |
| 5 Yıllık Değişim | 51.59% |
| Halka arzdan bu yana değişim | -99.12% |
Son Haberler & Güncellemeler
Anlatı Güncellemesi • Jun 25
PLX: Maintained Fair Value And 2026 Revenue Mix Will Support Upside
Analysts have maintained their fair value estimate for Protalix BioTherapeutics at $11.00, making only slight adjustments to the discount rate and long-term assumptions that leave the overall price target effectively unchanged. What's in the News Protalix BioTherapeutics reaffirmed its total revenue guidance for 2026 in the range of approximately US$78.0 million to US$83.0 million, according to a recent corporate guidance update.Anlatı Güncellemesi • Jun 05
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts have kept their $11.00 price target for Protalix BioTherapeutics unchanged, citing a mix of softer revenue growth and profit margin expectations, along with a very large projected future P/E multiple that offsets only modest tweaks to the discount rate in their models. What's in the News Protalix BioTherapeutics reaffirmed its 2026 total revenue guidance, projecting US$78.0 million to US$83.0 million, which includes a US$25.0 million milestone payment already received from Chiesi.Anlatı Güncellemesi • May 11
PLX: Extended Dosing Approval And 2026 Outlook Will Support Further Upside
Analysts kept their $11.00 price target on Protalix BioTherapeutics unchanged, citing only minor adjustments in discount rate, revenue growth, profit margin, and future P/E assumptions that did not materially alter their overall view of the stock. What's in the News The European Commission approved a 2 mg/kg every 4 weeks dosing regimen for pegunigalsidase alfa (Elfabrio) in adults with Fabry disease who are stable on enzyme replacement therapy, extending the infusion interval from every 2 weeks to every 4 weeks (Key Developments).Recent updates
Anlatı Güncellemesi • Jun 25
PLX: Maintained Fair Value And 2026 Revenue Mix Will Support Upside
Analysts have maintained their fair value estimate for Protalix BioTherapeutics at $11.00, making only slight adjustments to the discount rate and long-term assumptions that leave the overall price target effectively unchanged. What's in the News Protalix BioTherapeutics reaffirmed its total revenue guidance for 2026 in the range of approximately US$78.0 million to US$83.0 million, according to a recent corporate guidance update.Anlatı Güncellemesi • Jun 05
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts have kept their $11.00 price target for Protalix BioTherapeutics unchanged, citing a mix of softer revenue growth and profit margin expectations, along with a very large projected future P/E multiple that offsets only modest tweaks to the discount rate in their models. What's in the News Protalix BioTherapeutics reaffirmed its 2026 total revenue guidance, projecting US$78.0 million to US$83.0 million, which includes a US$25.0 million milestone payment already received from Chiesi.Anlatı Güncellemesi • May 11
PLX: Extended Dosing Approval And 2026 Outlook Will Support Further Upside
Analysts kept their $11.00 price target on Protalix BioTherapeutics unchanged, citing only minor adjustments in discount rate, revenue growth, profit margin, and future P/E assumptions that did not materially alter their overall view of the stock. What's in the News The European Commission approved a 2 mg/kg every 4 weeks dosing regimen for pegunigalsidase alfa (Elfabrio) in adults with Fabry disease who are stable on enzyme replacement therapy, extending the infusion interval from every 2 weeks to every 4 weeks (Key Developments).Anlatı Güncellemesi • Apr 26
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts now set Protalix BioTherapeutics' price target at $11.00. The unchanged level reflects only minimal tweaks to inputs such as the discount rate, long term revenue growth, profit margin assumptions and future P/E expectations.Anlatı Güncellemesi • Apr 09
PLX: New Dosing Approval And 2026 Revenue Outlook Will Support Upside
Analysts have maintained their $11.00 price target for Protalix BioTherapeutics, citing relatively stable assumptions around fair value, discount rate, revenue growth, profit margin and future P/E as the basis for keeping their outlook unchanged. What's in the News The European Commission approves a 2 mg/kg every four weeks dosing regimen for pegunigalsidase alfa in adults with Fabry disease who are stable on enzyme replacement therapy, extending the infusion interval from every two weeks to every four weeks (Key Developments).Anlatı Güncellemesi • Mar 26
PLX: New Dosing Approval And 2026 Outlook Will Support Undervalued Upside
Analysts kept their $11.00 price target on Protalix BioTherapeutics unchanged, highlighting revised assumptions for revenue growth, profit margins, the discount rate and future P/E as key drivers behind their updated model. What's in the News Protalix BioTherapeutics issued 2026 total revenue guidance of approximately $78.0 million to $83.0 million, which includes a $25.0 million milestone payment from Chiesi tied to regulatory progress for Elfabrio (company guidance).Anlatı Güncellemesi • Mar 09
PLX: Extended Fabry Dosing Will Support Undervalued Long Term Outlook
Analysts have reiterated an $11.00 price target for Protalix BioTherapeutics, citing only slight tweaks to model inputs such as the discount rate, long-term revenue growth, profit margins, and future P/E assumptions rather than any major shift in their overall view. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics reported that the European Medicines Agency's Committee for Medicinal Product for Human Use issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen of pegunigalsidase alfa for adult Fabry patients who are stable on enzyme replacement therapy (Key Developments).Anlatı Güncellemesi • Feb 23
PLX: Fabry Dosing Extension Will Support Undervalued Long Term Outlook
Analysts are maintaining their $11.00 price target for Protalix BioTherapeutics while slightly refining core modeling inputs such as the discount rate, long term revenue growth, profit margin and future P/E assumptions to better align with their updated risk and earnings outlook. What's in the News CHMP of the EMA issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen for pegunigalsidase alfa in adult Fabry disease patients who are stable on enzyme replacement therapy, potentially giving eligible patients a longer interval between infusions (Product related announcement).Anlatı Güncellemesi • Feb 08
PLX: Renal ASO Pipeline And Fabry Dosing Expansion Will Drive Upside
Analysts have maintained their price target for Protalix BioTherapeutics at US$11.00, citing a combination of updated assumptions regarding the discount rate, revenue growth, profit margins, and a higher future P/E multiple as reasons to keep their existing valuation view. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics reported that the EMA's Committee for Medicinal Products for Human Use issued a positive opinion recommending approval of a 2 mg/kg every 4 weeks dosing regimen of pegunigalsidase alfa for adult Fabry patients who are stable on enzyme replacement therapy, aiming to extend time between infusions so patients can focus more on daily life (Key Developments).Anlatı Güncellemesi • Jan 24
PLX: Renal ASO Collaboration Will Drive Next Phase Of Upside Potential
Analysts have maintained their US$11.00 price target for Protalix BioTherapeutics, citing only slight adjustments to their discount rate, long term revenue growth, profit margin assumptions and future P/E outlook, rather than any major shift in their thesis. What's in the News Protalix BioTherapeutics and Secarna Pharmaceuticals entered a collaboration and option agreement to discover antisense oligonucleotide therapies targeting rare renal indications, with Secarna using its OligoCreator platform to design and profile candidates and Protalix selecting the biological targets (Key Developments).Anlatı Güncellemesi • Jan 10
PLX: Renal Collaboration Agreement Will Drive Next Phase Of Upside Potential
Analysts have maintained their fair value estimate for Protalix BioTherapeutics at US$11.00. This reflects only minor adjustments to assumptions around discount rate, revenue growth, profit margins and future P/E that do not materially change their overall view.Anlatı Güncellemesi • Dec 16
PLX: European Label Expansion Review Will Drive Next Phase Of Upside Potential
Analysts have nudged their price target on Protalix BioTherapeutics slightly higher to $11.00, reflecting marginal adjustments to discount rate, long term growth, and profitability assumptions, while maintaining a broadly consistent valuation framework. What's in the News Chiesi Global Rare Diseases and Protalix BioTherapeutics requested re examination of the EMA CHMP negative opinion on adding a once every 4 weeks 2 mg/kg Elfabrio dosing regimen to the currently approved every 2 weeks regimen, seeking broader label flexibility in Europe (Key Developments) Safety data from Elfabrio clinical trials highlighted hypersensitivity reactions in 14 percent of treated patients and anaphylaxis in 3 percent, underscoring the need for careful infusion monitoring and potential dose adjustments (Key Developments) Additional clinical observations included infusion associated reactions in 29 percent of Elfabrio patients and a reported case of membranoproliferative glomerulonephritis, prompting recommendations to monitor renal function and infusion related symptoms (Key Developments) Protalix BioTherapeutics was added to the S&P Global BMI Index, potentially increasing its visibility and accessibility to global institutional investors (Key Developments) Valuation Changes Fair value estimate maintained at $11.00 per share, indicating no change to the analyst target price.Anlatı Güncellemesi • Dec 02
PLX: European Regulatory Review Will Unlock Next Phase Of Upside Potential
Analysts have lowered their price target for Protalix BioTherapeutics from $12.50 to $11.00, citing a slight reduction in expected revenue growth and profit margins. What's in the News Protalix BioTherapeutics and Chiesi Global Rare Diseases have requested a re-examination of the negative opinion by the European Medicines Agency regarding the new dosing regimen for Elfabrio.Anlatı Güncellemesi • Nov 18
PLX: European Review Process Will Drive Next Phase Of Momentum
Analysts have lowered their price target for Protalix BioTherapeutics from $14.00 to $12.50. They cite more conservative expectations regarding revenue growth and profit margins.
Yeni Anlatı • May 19
Protalix BioTherapeutics aims for $3.20 by year-end amidst strong revenue growth
As of right now the stock as a current yield of about 2.42%, with a return on equity of about 6.79%. So a bit off of my goals of at least 5% and 10%. However over the last 3 years revenue has grown on
Yeni Anlatı • Apr 29
PRX-115 Trials And Elfabrio Launch Will Open Future Markets
Successful Phase II trials and Chiesi's involvement with Elfabrio could drive growth through new marketable products and increased market adoption.Analiz Makalesi • Feb 22
Analysts Expect Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) To Breakeven Soon
We feel now is a pretty good time to analyse Protalix BioTherapeutics, Inc.'s ( NYSEMKT:PLX ) business as it appears...Analiz Makalesi • Jan 14
Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?
It is not uncommon to see companies perform well in the years after insiders buy shares. Unfortunately, there are also...Analiz Makalesi • Dec 10
Could The Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Ownership Structure Tell Us Something Useful?
A look at the shareholders of Protalix BioTherapeutics, Inc. ( NYSEMKT:PLX ) can tell us which group is most powerful...Hissedar Getirileri
| PLX | US Biotechs | US Pazar | |
|---|---|---|---|
| 7D | -0.4% | -0.4% | -1.4% |
| 1Y | 56.6% | 35.0% | 17.4% |
Getiri vs. Endüstri: PLX geçen yıl % 35 oranında getiri sağlayan US Biotechs sektörünü aştı.
Getiri vs Piyasa: PLX geçen yıl % 17.4 oranında getiri sağlayan US Piyasasını aştı.
Fiyat Oynaklığı
| PLX volatility | |
|---|---|
| PLX Average Weekly Movement | 6.0% |
| Biotechs Industry Average Movement | 10.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.2% |
İstikrarlı Hisse Senedi Fiyatı: PLX son 3 ayda US piyasasına kıyasla önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: PLX 'nin haftalık oynaklığı ( 6% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında
| Kuruldu | Çalışanlar | CEO | Web sitesi |
|---|---|---|---|
| n/a | 226 | Dror Bashan | www.protalix.com |
Bir biyofarmasötik şirketi olan Protalix BioTherapeutics, Inc. ProCellEx bitki hücresi tabanlı protein ekspresyon sistemine dayalı rekombinant terapötik proteinlerin geliştirilmesi, üretimi ve ticarileştirilmesi ile ilgilenmektedir. Şirket, Gaucher hastalığının tedavisi için Elelyso ve Fabry hastalığı tanısı doğrulanmış yetişkin hastaların tedavisi için Elfabrio ürünlerini sunmaktadır. Ayrıca gut hastalığının tedavisi için Faz 2 denemesinde olan bitki hücresi eksprese rekombinant PEGile Ürikaz PRX-115 ve nötrofil ekstraselüler tuzak hastalıklarının tedavisi için bitki hücresi eksprese PEGile rekombinant insan DNaz I ürün adayı PRX-119'u geliştirmektedir.
Protalix BioTherapeutics, Inc. Temel Bilgiler Özeti
| PLX temel i̇stati̇sti̇kler | |
|---|---|
| Piyasa değeri | US$191.76m |
| Kazançlar(TTM) | US$15.33m |
| Gelir(TTM) | US$76.38m |
12.5x
F/K Oranı2.5x
P/S OranıPLX aşırı değerli mi?
Gerçeğe Uygun Değer ve değerleme analizine bakınızKazanç ve Gelir
| PLX gelir tablosu (TTM) | |
|---|---|
| Gelir | US$76.38m |
| Gelir Maliyeti | US$41.83m |
| Brüt Kâr | US$34.55m |
| Diğer Giderler | US$19.22m |
| Kazançlar | US$15.33m |
Son Raporlanan Kazançlar
Mar 31, 2026
Sonraki Kazanç Tarihi
n/a
| Hisse başına kazanç (EPS) | 0.19 |
| Brüt Marj | 45.24% |
| Net Kâr Marjı | 20.07% |
| Borç/Özkaynak Oranı | 0% |
PLX uzun vadede nasıl bir performans gösterdi?
Geçmiş performansı ve karşılaştırmayı görünŞirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/07/20 16:10 |
| Gün Sonu Hisse Fiyatı | 2026/07/17 00:00 |
| Kazançlar | 2026/03/31 |
| Yıllık Kazançlar | 2025/12/31 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına Github sayfamızdan ulaşabilirsiniz; ayrıca raporlarımızı nasıl kullanacağınıza dair kılavuzlarımız ve YouTube’da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Protalix BioTherapeutics, Inc. 8 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Ritu Baral | Canaccord Genuity |
| Raghuram Selvaraju | H.C. Wainwright & Co. |
| Peter Welford | Jefferies LLC |